Loading…
Loading…
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 46,353 shares, a drop of 81.8% from the July 15th total of 255,103 shares. Based on an average daily volume of 113,253
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award.
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syringes and vials per year.
SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA) A List for the second consecutive year. The recognition highlights the company's leadership in engaging suppliers on climate-related issues and reflects its strong performance in governance, target-setting, Scope 3 emissions disclosure, and value chain engagement.
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facility has since progressed seamlessly into operation, completing multiple engineering and GMP batches, delivering clinical supplies to support the client's regulatory filings and clinical development needs.
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets). Through S&P Global's Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index identify sustainability leaders that rank in the top 10% based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.
No recent filings indexed.